Zepbound Alternatives: Compounded Tirzepatide, Wegovy, and Mounjaro, Compared

Is there a generic Zepbound?

No — not yet, and not imminently, despite headlines that make it sound closer than it is. As of this check, Eli Lilly's patents on tirzepatide (the active ingredient in both Zepbound and Mounjaro) run through 2036, and no generic version has cleared FDA approval. Sandoz has two abbreviated new drug applications the FDA agreed to review, accepted June 29, 2026; Amneal filed for a generic tirzepatide autoinjector, accepted July 8, 2026. Both are real developments, but "FDA accepted the application for review" is a long way from "generic on the shelf" — an accepted ANDA sits behind Lilly's patent portfolio until a Paragraph IV patent challenge succeeds or a licensing deal is struck, neither of which has happened yet. If you're holding out for a generic before treating cost as a real problem, the honest answer is: not this year, and not with a confirmed date even for next year.

That's also the reason this page exists — with no generic to point to, the real cost and access alternatives are compounded tirzepatide (the same molecule, a different regulatory pathway), a different GLP-1 brand entirely, or accepting Zepbound's own price and working the insurance and savings-card angles covered on Zepbound cost.

Is Zepbound actually out of stock right now?

Less often than the compounding industry's marketing implies. The FDA declared the tirzepatide shortage resolved in October 2024, and by 2026 most doses are consistently available through LillyDirect and standard retail pharmacies — spot shortages of specific doses or pen configurations still surface occasionally, but a blanket "Zepbound is out of stock" claim is usually a sales pitch for a compounded alternative rather than a current, verified fact. If your specific pharmacy is out, LillyDirect's own self-pay program and Walmart pickup option are worth checking before assuming the drug itself is unavailable nationally.

Compounded tirzepatide: the same molecule, for less — is it legal, and is it worth it?

This is the closest thing to a true Zepbound substitute, because it's not really a substitute at all — it's the same active molecule, tirzepatide, prepared by a licensed 503A pharmacy for a specific, named patient instead of manufactured by Eli Lilly as an FDA-approved finished drug. Curex currently holds the lowest verified all-in price among the major providers, at roughly $199 a month with medication, consult, and shipping bundled and no separate membership fee — though that's a starter-dose rate, and the maintenance-dose ladder isn't publicly posted, so confirm it before you enroll.

The legal ground shifted hard in 2025 and is worth understanding before price alone decides this for you. Once the FDA declared the tirzepatide shortage resolved, the broad compounding that fueled a wave of cheap telehealth tirzepatide lost its basis — 503B outsourcing facilities had to wind down by March 19, 2025. What survives is narrower: a 503A pharmacy can still compound tirzepatide for a specific patient when a prescriber documents a real clinical reason the commercial product doesn't meet, most commonly an allergy to an inactive ingredient in Zepbound's formulation. Cost alone isn't a qualifying reason under current FDA guidance, even though cost is the reason most people go looking. Layered on top, the FDA proposed on April 30, 2026 to remove tirzepatide from the 503B bulk-substances list entirely; the comment period closed July 30, 2026, and as of this check no final rule has been issued — that proposal concerns 503B bulk compounding specifically, which has already stopped in practice, so it doesn't change the narrower 503A pathway most current providers operate under.

For the full seven-provider price comparison — Curex, Mochi Health, Eden, Fridays, Willow, Henry Meds, and Peak Wellness, all-in monthly cost — see compounded tirzepatide providers compared rather than re-listing that roster here.

Wegovy vs. Zepbound: is semaglutide a real substitute, or a downgrade?

Wegovy is a real substitute, not a knockoff — it's just a different molecule with a genuinely different average result, and it's honest to say so plainly rather than pretend the two are interchangeable. Both are GLP-1 receptor agonists, but Zepbound's tirzepatide also activates a second receptor, GIP, that Wegovy's semaglutide doesn't touch. In SURMOUNT-5, the first trial to test the two molecules head-to-head in the same protocol, tirzepatide produced about 20% average weight loss at 72 weeks against about 14% for semaglutide. A newer, higher semaglutide dose (Wegovy HD, 7.2mg, FDA-approved March 2026) narrowed that gap to roughly 17.5–20.7% in its own separate trial — but that's a cross-trial comparison, not a rematch, so the honest read is that Zepbound still holds the only true head-to-head win, not that the gap has closed.

Where Wegovy pulls ahead is price and format. Its self-pay ladder undercuts Zepbound's at every comparable tier — $149 to $299 a month for the oral tablet by dose, or $199 for a new patient's first two pen fills stepping up to $349 or $399 — and it's the only one of the two with an FDA-approved once-daily pill, a real option if avoiding needles matters as much to you as the medication itself. Both converge at the same $25 a month if your commercial insurance covers the drug and you're using the manufacturer's savings card, which is the scenario where cost stops being the deciding factor between them entirely. For the full molecule-level breakdown — mechanism, both drugs' second FDA indications, and the complete price ladder — see Wegovy cost.

Mounjaro vs. Zepbound: same drug, different insurance door

This is the alternative that trips people up most, because Mounjaro and Zepbound aren't really two different drugs — they're the identical molecule, tirzepatide, from the identical manufacturer, at identical dose strengths. The only real difference is the FDA approval attached to each brand name: Mounjaro for type 2 diabetes, Zepbound for chronic weight management. That single regulatory split decides almost everything about price and access from there.

If your prescriber can document a type 2 diabetes diagnosis and your commercial plan covers Mounjaro under that indication, the Lilly Savings Card can bring it down to $25 a month — often the single cheapest tirzepatide route on this entire page, cheaper even than compounded. But that card requires the T2D-coded prescription specifically; a weight-loss-only script doesn't qualify, and the card excludes government insurance entirely. Without a diabetes diagnosis and without coverage, Mounjaro's retail price runs about $1,060 to $1,090 a month — Eli Lilly has never built a LillyDirect-style self-pay vial program for the Mounjaro brand the way it has for Zepbound, so there's no cheaper cash-pay ladder to fall back on with this brand specifically. In that scenario, Zepbound's own $299–$449 self-pay ladder is the better cash-pay option even though it's the more expensive brand on paper before insurance enters the picture. See Mounjaro cost for the complete nine-way price breakdown.

OTC "GLP-1" pills, patches, and gummies: what they actually are (and aren't)

This is the category worth the most skepticism, and it's worth being direct about it: no over-the-counter product sold as a "natural GLP-1" or a Zepbound alternative delivers anything close to what tirzepatide, semaglutide, or even compounded versions of either actually do. The most common ingredient behind these claims is berberine, a plant alkaloid regulated in the US as a dietary supplement, not a drug — meaning it never goes through the FDA review that verifies a prescription medication's purity, potency, or efficacy before it reaches a shelf. Berberine does have real, modest evidence for blood sugar control, via a pathway called AMPK that resembles metformin's mechanism more than it resembles a GLP-1 receptor agonist's. What it does not have is meaningful weight-loss evidence at anywhere near GLP-1 scale — trials report roughly 1 to 4 kilograms of average weight loss, a small fraction of tirzepatide's roughly 20% of body weight in its own trials. "Nature's Ozempic" or "nature's Zepbound" is a marketing label, not a mechanistic description.

"GLP-1 patches" specifically deserve a harder no. Estradiol, used in hormone therapy, is a small, fat-soluble molecule that genuinely crosses intact skin — that's real pharmacology, and it's why an estrogen patch works. GLP-1 medications are peptides: large chains of amino acids that intact skin is specifically built to block. A patch has no real mechanism to deliver a peptide like tirzepatide or semaglutide into your bloodstream at all, regardless of what the label claims. Gummies, drops, and other novelty formats marketed with "GLP-1" in the name are almost always the same repackaged supplement ingredients — berberine, chromium, glucomannan — under a trendier label, sold in a genuinely unregulated corner of the supplement market where quality and dosing consistency vary by manufacturer in ways a prescription drug's don't.

• No prescription, consult, or bloodwork required at any point before purchase
• Sold via Amazon, TikTok Shop, or a direct-response ad rather than a licensed telehealth platform or pharmacy
• "Nature's Ozempic" or "GLP-1" in the name with no named active pharmaceutical ingredient or dose printed anywhere on the label
• A patch, gummy, or drop claiming to deliver tirzepatide or semaglutide itself, rather than an unrelated supplement ingredient
• Price far below even compounded tirzepatide's ~$199/mo floor for something claiming equivalent results

None of this means every supplement in this space is a scam outright, and berberine specifically has a real, if narrow, evidence base worth raising with a prescriber for blood-sugar support alongside — not instead of — an actual GLP-1 if that's the goal. But treating any OTC product as a cost-saving swap for Zepbound itself is the one substitution on this page that doesn't hold up, no matter how tight the budget.

So which Zepbound alternative actually makes sense for you?

• Zepbound is unaffordable but you want to stay on the identical molecule: compounded tirzepatide through a provider like Curex is the closest real substitute, at roughly $199/mo — understand the narrower legal footing before you enroll.
• You're needle-averse and weight loss, not a specific molecule, is the goal: Wegovy's oral tablet, from $149/mo self-pay, is the only FDA-approved once-daily pill in this comparison — Zepbound has no pill option at all.
• You have a documented type 2 diabetes diagnosis and commercial insurance: ask specifically about Mounjaro and the Lilly Savings Card — $25/mo if your plan covers it, often the cheapest tirzepatide route on this page.
• Your insurance covers Zepbound already: the Zepbound Savings Card at ~$25/mo beats every alternative here outright — confirm coverage before shopping elsewhere.
• You want the strongest average trial result and cost is secondary: nothing on this page beats tirzepatide's own SURMOUNT-5 result — Zepbound itself, at whichever price tier you qualify for, remains the strongest single option by the numbers.
• You're tempted by a cheap OTC "GLP-1" pill, patch, or gummy: it isn't a substitute for any option above — treat the savings as illusory and the product as, at best, an unrelated supplement wearing a GLP-1 label.

Annual cost math across every real alternative

• Zepbound Savings Card, insured and covered: about $300/yr ($25/mo).
• Compounded tirzepatide, Curex starter rate: about $2,388/yr (~$199/mo).
• Zepbound, LillyDirect self-pay, maintenance dose: about $5,388/yr ($449/mo).
• Wegovy, NovoCare self-pay pill, top dose: about $3,588/yr ($299/mo) — roughly $1,800/yr less than Zepbound's equivalent self-pay tier.
• Mounjaro + Lilly Savings Card, insured T2D-covered: about $300/yr ($25/mo) — matches Zepbound's best-case insured tier, but only with a qualifying diagnosis.
• Mounjaro, retail, uninsured: roughly $12,720–$13,080/yr — the most expensive real option on this page, since no self-pay ladder exists for this brand.